• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    4/25/24 4:32:50 PM ET
    $ACON
    $BFRG
    $DARE
    $DXCM
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Tevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. The company's market cap stands at $212.3 million.
    • Fresh2 Group (NASDAQ:FRES) stock rose 10.61% to $0.64. The company's market cap stands at $15.6 million.
    • ResMed (NYSE:RMD) stock rose 6.85% to $196.0. The market value of their outstanding shares is at $28.8 billion. The company's, Q3 earnings came out today.
    • MSP Recovery (NASDAQ:LIFW) shares increased by 5.51% to $0.99. The market value of their outstanding shares is at $15.6 million.
    • Gossamer Bio (NASDAQ:GOSS) stock increased by 4.99% to $0.7. The market value of their outstanding shares is at $158.6 million.
    • Telesis Bio (NASDAQ:TBIO) shares increased by 4.98% to $0.35. The market value of their outstanding shares is at $10.4 million.

    Losers

    • Vincerx Pharma (NASDAQ:VINC) shares declined by 17.5% to $0.74 during Thursday's after-market session. The company's market cap stands at $15.8 million.
    • Aclarion (NASDAQ:ACON) stock declined by 16.56% to $0.33. The market value of their outstanding shares is at $2.3 million.
    • DexCom (NASDAQ:DXCM) stock decreased by 8.7% to $126.01. The company's market cap stands at $49.9 billion. As per the press release, Q1 earnings came out today.
    • Dare Bioscience (NASDAQ:DARE) shares fell 7.99% to $0.27. The market value of their outstanding shares is at $26.7 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares declined by 7.41% to $1.0. The market value of their outstanding shares is at $1.4 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock decreased by 6.3% to $2.68. The company's market cap stands at $21.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $BFRG
    $DARE
    $DXCM

    CompanyDatePrice TargetRatingAnalyst
    DexCom Inc.
    $DXCM
    3/24/2026$90.00In-line → Outperform
    Evercore ISI
    Gossamer Bio Inc.
    $GOSS
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2026Buy → Hold
    D. Boral Capital
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    DexCom Inc.
    $DXCM
    1/12/2026$71.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $ACON
    $BFRG
    $DARE
    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

    SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com•Date:1:30 p.m. PT / 4:30 p.m. ET•Time:London, Thursday, April 30, 2026, 9:30 p.m. BST•International:Sydney, Friday, May 1, 2026, 6:30 a.m. AEST    Please note, Resmed does not use outside phone lines t

    4/1/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

    3/31/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    $ACON
    $BFRG
    $DARE
    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $BFRG
    $DARE
    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dexcom upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Dexcom from In-line to Outperform and set a new price target of $90.00

    3/24/26 9:07:04 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Gossamer Bio downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral

    3/23/26 8:26:50 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tevogen Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Tevogen Bio from Buy to Hold

    3/4/26 9:36:27 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $BFRG
    $DARE
    $DXCM
    SEC Filings

    View All

    SEC Form QUALIF filed by Dare Bioscience Inc.

    QUALIF - Dare Bioscience, Inc. (0001401914) (Filer)

    4/2/26 12:15:02 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by ResMed Inc.

    144 - RESMED INC (0000943819) (Subject)

    4/1/26 5:30:15 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Bullfrog AI Holdings Inc.

    424B5 - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    4/1/26 4:42:42 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $BFRG
    $DARE
    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Aranda Richard

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:22:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Peterson Caryn

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:20:55 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Smith Robert Paul Jr

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:19:57 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $BFRG
    $DARE
    $DXCM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $BFRG
    $DARE
    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

    WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month. Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients. Tevogen continues to prioritize the development of TVGN 489,

    3/11/26 3:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Names Leadership Team to Execute Diversified Growth Strategy

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek StobinskiGene

    3/9/26 7:45:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dexcom Appoints Rick Osterloh to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und

    2/26/26 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $ACON
    $BFRG
    $DARE
    $DXCM
    Financials

    Live finance-specific insights

    View All

    Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

    SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com•Date:1:30 p.m. PT / 4:30 p.m. ET•Time:London, Thursday, April 30, 2026, 9:30 p.m. BST•International:Sydney, Friday, May 1, 2026, 6:30 a.m. AEST    Please note, Resmed does not use outside phone lines t

    4/1/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

    Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

    3/26/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

    SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website

    3/20/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $BFRG
    $DARE
    $DXCM
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $BFRG
    $DARE
    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care